Preclinical data for the small molecule drug vidofludimus calcium has revealed its activity in relation to a neuroprotective transcription factor in addition to its ability to inhibit an enzyme which plays a key role in the metabolism of overactive immune cells and virus-infected cells, Immunic Inc announced on 17 May. The findings have been published in the Journal of Medicinal Chemistry.
